Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifamycin Sodium

FDA-approved product (tablet, delayed release, oral), marketed as Aemcolo.

Registered studies
43
Lab records
6
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rifamycin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diarrhea
  • Eye infection
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Other antibiotics for topical use; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB03; WHO ATC A07AA13; WHO ATC D06AX15; WHO ATC S01AA16

Repurposing investigation

Rifamycin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA96.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli74.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae16.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis93.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 1 of 2 lab records
  • K. pneumoniae: measured active in 0 of 1 lab record
  • M. tuberculosis: measured active in 1 of 1 lab record
Open Rifamycin Sodium in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifamycin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rifamycin in Minimal Hepatic Encephalopathy

    NCT04082780 · start 2019-09-01

    Registered record
    Registry ID
    NCT04082780
    Conditions
    Hepatic Encephalopathy; Cirrhosis, Liver
    Interventions
    Rifamycin SV MMX; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-09-01
    Completion
    2023-04-28
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy; Cirrhosis, Liver
    InterventionRifamycin SV MMX; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

    NCT03474029 · start 2019-08-01

    Registered record
    Registry ID
    NCT03474029
    Conditions
    Latent Tuberculosis
    Interventions
    Rifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks; Rifampin and Isoniazid daily for 12 weeks; Rifampin daily for 16 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2019-08-01
    Completion
    2029-12-31
    Enrolment
    3,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis
    InterventionRifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks; Rifampin and Isoniazid daily for 12 weeks; Rifampin daily for 16 weeks
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Doravirine, Rifapentine and Isoniazid Interaction

    NCT03886701 · start 2019-04-22

    Registered record
    Registry ID
    NCT03886701
    Conditions
    Latent Tuberculosis; Human Immunodeficiency Virus; Rifamycins Causing Adverse Effects in Therapeutic Use; Drug Interaction Potentiation
    Interventions
    Doravirine (DOR); Rifapentine (RPT); Isoniazid (INH)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-22
    Completion
    2019-05-20
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; Human Immunodeficiency Virus; Rifamycins Causing Adverse Effects in Therapeutic Use; Drug Interaction Potentiation
    InterventionDoravirine (DOR); Rifapentine (RPT); Isoniazid (INH)
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

    NCT03814200 · start 2019-01-03

    Registered record
    Registry ID
    NCT03814200
    Conditions
    Healthy Subject
    Interventions
    Saline; ACT-246475; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-03
    Completion
    2019-02-19
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subject
    InterventionSaline; ACT-246475; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of the Effects of Irrigation of the Extraction Socket With Rifamycine

    NCT04349579 · start 2018-11-15

    Registered record
    Registry ID
    NCT04349579
    Conditions
    Impacted Third Molar Tooth
    Interventions
    Rifamycine; Saline Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-11-15
    Completion
    2023-12-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpacted Third Molar Tooth
    InterventionRifamycine; Saline Solution
    PhasePhase 4
    Registry statusUnknown

  • A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

    NCT03596294 · start 2018-07-19

    Registered record
    Registry ID
    NCT03596294
    Conditions
    Healthy Subjects
    Interventions
    Clazosentan; Rifampicin; Saline (0.9% sodium chloride)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-19
    Completion
    2018-08-03
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionClazosentan; Rifampicin; Saline (0.9% sodium chloride)
    PhasePhase 1
    Registry statusCompleted

  • Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

    NCT03510468 · start 2018-06-12

    Registered record
    Registry ID
    NCT03510468
    Conditions
    Healthy Volunteers
    Interventions
    Tenofovir alafenamide; Rifapentine; Isoniazid (INH); Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-12
    Completion
    2022-12-21
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTenofovir alafenamide; Rifapentine; Isoniazid (INH); Pyridoxine
    PhasePhase 1
    Registry statusCompleted

  • Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease

    NCT04730245 · start 2018-06-01

    Registered record
    Registry ID
    NCT04730245
    Conditions
    Parkinson's Disease Aggravated
    Interventions
    sodium phosphate enema, oral rifaximin and polyethylene glycol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-01
    Completion
    2020-03-30
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Aggravated
    Interventionsodium phosphate enema, oral rifaximin and polyethylene glycol
    PhasePhase 1
    Registry statusCompleted

  • Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

    NCT03099785 · start 2017-12-18

    Registered record
    Registry ID
    NCT03099785
    Conditions
    Diarrhea-predominant Irritable Bowel Syndrome
    Interventions
    Rifamycin SV 600mg t.i.d.; Rifamycin SV b.i.d. + Placebo; Placebo t.i.d.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-12-18
    Completion
    2020-12-14
    Enrolment
    279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea-predominant Irritable Bowel Syndrome
    InterventionRifamycin SV 600mg t.i.d.; Rifamycin SV b.i.d. + Placebo; Placebo t.i.d.
    PhasePhase 2
    Registry statusCompleted

  • Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

    NCT03149848 · start 2017-06-06

    Registered record
    Registry ID
    NCT03149848
    Conditions
    Infection, Human Immunodeficiency Virus; HIV Infections
    Interventions
    Cabotegravir; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-06
    Completion
    2017-09-07
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus; HIV Infections
    InterventionCabotegravir; Rifabutin
    PhasePhase 1
    Registry statusCompleted

  • Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

    NCT02651259 · start 2017-03-13

    Registered record
    Registry ID
    NCT02651259
    Conditions
    Tuberculosis
    Interventions
    Rifapentine (RPT); Isoniazid (INH); Pyridoxine (vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-03-13
    Completion
    2019-04-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine (RPT); Isoniazid (INH); Pyridoxine (vitamin B6)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

    NCT02771249 · start 2016-06-03

    Registered record
    Registry ID
    NCT02771249
    Conditions
    HIV Infected Population With Latent Tuberculosis
    Interventions
    rifapentene (RPT); darunavir/cobicistat (DRV/c); Isoniazid (INH); Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06-03
    Completion
    2021-08-17
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infected Population With Latent Tuberculosis
    Interventionrifapentene (RPT); darunavir/cobicistat (DRV/c); Isoniazid (INH); Pyridoxine
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

    NCT02563327 · start 2016-01-25

    Registered record
    Registry ID
    NCT02563327
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Moxifloxacin; Rifampin; Isoniazid; Pyrazinamide; Ethambutol; Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-08-30
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Moxifloxacin; Rifampin; Isoniazid +3 more
    PhasePhase 3
    Registry statusCompleted

  • Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates

    NCT03528915 · start 2015-09-09

    Registered record
    Registry ID
    NCT03528915
    Conditions
    Ophthalmia Neonatorum
    Interventions
    Rifamycine treatment; whithout Rifamycine treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-09-09
    Completion
    2016-07-24
    Enrolment
    881

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOphthalmia Neonatorum
    InterventionRifamycine treatment; whithout Rifamycine treatment
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers

    NCT02969252 · start 2015-07

    Registered record
    Registry ID
    NCT02969252
    Conditions
    Healthy
    Interventions
    Rifamycin SV-MMX® 600
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-07
    Completion
    Not recorded
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRifamycin SV-MMX® 600
    PhasePhase 1
    Registry statusCompleted